anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The live attenuated vaccine P7-P8 strain against herpesviral haematopoietic necrosis, which is caused by cyprinid herpesvirus 2 (CyHV-2), exhibits high protective efficacy in goldfish at 25°C, the predominant temperature for this disease; however, the effect of water temperature during the vaccination period on efficacy has not been determined. In this study, an in vitro experiment revealed that the vaccine strain grew between 15 and 30°C in the goldfish cell line RyuF-2. Subsequent in vivo efficacy tests were conducted with vaccination temperatures ranging from 15 to 30°C. During the vaccination period, organs were sampled to determine the vaccine growth dynamics. Blood plasma was collected to assess anti-CyHV-2 antibody titres. The protective efficacy of the vaccine at 15, 20, 25, and 30°C after subsequent virulent CyHV-2 challenge resulted in a relative percentage survival of 73.3%, 77.8%, 100%, and 77.8%, respectively, which indicated that the vaccine is effective over this temperature range. The vaccine virus load in the spleen was lowest at 15°C (103.7 DNA copies/mg) and highest at 25°C (106.5 DNA copies/mg). This indicates that the vaccine virus load over 104 DNA copies/mg may elicit sufficient acquired immunity. No significant differences in antibody titre were observed between groups, which suggests that cell-mediated immunity can be fundamentally involved in protection.
An oral preparation of compound fat emulsion belongs to a nutritious product which is confected by a prescription. The raw material includes midchain fatty acid glyceride (MCT), calcium caseinate/sodium peptide caseinate, refined egg yolk lecithin, pharmaceutical glycerin and purified water. The prescription is 10 to 200 g of the MCT, 0 to 30 g of the calcium caseinate or the sodium peptide caseinate, 0 to 30 g of the refined egg yolk lecithin, 0 to 50 g of the pharmaceutical glycerin, 0 to 100 g of camelina oil and 0 to 200 g of salad oil, and the purified water is added till 1000ml. The total content of fat is not less than 80 percent, wherein the MCT is not less than 20 percent. The oral preparation mainly reinforces the thermal energy as well as can regulate the blood fat and improve the energy metabolism status. The oral preparation is mainly used for health care and intestinal nourishment and used to remedy the primary malnutrition and the pathological malnutrition, which is capable of promptly improving the energy and nourishment supply status, improving the antiviral ability, strengthening the immunity function, reducing the complications, shortening the time of being in hospital, reducing the treatment cost and improving the clinically comprehensive curative effect.
Ammonia levels are orchestrated by a series of complex interrelated pathways in which the urea cycle has a central role. Liver dysfunction leads to an accumulation of ammonia, which is toxic and is strongly associated with disruption of potassium homeostasis, mitochondrial dysfunction, oxidative stress, inflammation, hypoxaemia and dysregulation of neurotransmission. Hyperammonaemia is a hallmark of hepatic encephalopathy and has been strongly associated with liver-related outcomes in patients with cirrhosis and liver failure. In addition to the established role of ammonia as a neurotoxin in the pathogenesis of hepatic encephalopathy, an increasing number of studies suggest that it can lead to hepatic fibrosis progression, sarcopenia, immune dysfunction and cancer. However, elevated systemic ammonia levels are uncommon in patients with metabolic dysfunction-associated steatotic liver disease. A clear causal relationship between ammonia-induced immune dysfunction and risk of infection has not yet been definitively proven. In this Review, we discuss the mechanisms by which ammonia produces its diverse deleterious effects and their clinical relevance in liver diseases, the importance of measuring ammonia levels for the diagnosis of hepatic encephalopathy, the prognosis of patients with cirrhosis and liver failure, and how our knowledge of inter-organ ammonia metabolism is leading to the development of novel therapeutic approaches.
Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and vinorelbine ditartrate IV over 5-10 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
INTRODUCTION: Simultaneous pancreas-kidney transplantation (SPK) is the preferred treatment for individuals with type-1 diabetes and end-stage renal disease. However, a limited supply of "Ideal Pancreas Donors" contributed to a growing disparity between available organs and recipients. Even though SPK outcomes from pediatric donors match those from adult donors, unclear guidelines on minimum age and weight criteria for extra small pediatric pancreas donors lead to hesitancy among several transplant centers to utilize these grafts due to concerns about inadequate islet mass, technical challenges, and increased risk of allograft thrombosis.
METHODS: This report details the successful outcomes of SPK transplantations performed at the study center between December 2021 and January 2024, using four extra small pediatric brain-dead donors (ESPDs). Each donor was aged ≤5 years and weighed <20 kg.
RESULTS: All SPK recipients achieved immediate posttransplant euglycemia without requiring insulin. None of the recipients experienced graft pancreatitis, graft thrombosis, allograft rejection, or required re-exploration. During a 5-27-month follow-up period, all ESPD recipients maintained optimal graft function, as evidenced by normal glucose tolerance tests and HbA1c (4.9%-5.2%), with 100% graft and patient survival.
CONCLUSION: This report examines the usage of ESPDs in SPK transplantation, highlighting their potential to expand the donor pool and reduce wait times in areas with scarce deceased organ donations, thereby increasing the number of available organs for transplantation with acceptable outcomes. Revising donor selection guidelines to reflect the diverse risk-benefit profiles of waitlisted individuals is crucial to addressing geographical disparities and reducing organ discard rates.
Previous studies have confirmed that Aerobic exercise rehabilitation can reduce the rate of readmission of patients with heart failure and improve their cardiopulmonary endurance and exercise ability. However, whether aerobic exercise rehabilitation can inhibit myocardial fibrosis or delay the progress of fibrosis in patients with heart failure has not been reported. At the same time, some studies have shown that the change of intestinal microbial flora may promote the progress of heart failure, and regular aerobic exercise will also lead to the change of intestinal microbial flora, but whether aerobic exercise rehabilitation can improve intestinal microbial flora in patients with dilated cardiomyopathy has not been reported. In our study, patients who were hospitalized for heart failure for the first time and were finally diagnosed with dilated cardiomyopathy were recruited. Recruited patients will enter the routine cardiac rehabilitation process and make an individualized aerobic exercise plan according to the cardiopulmonary exercise test. Cardiac MRI and intestinal microflora changes will be evaluated.
Behavioral interventions for chronic pain among people living with HIV (PLWH) are an understudied area, with great potential to improve pain and function. Chronic pain is an important comorbidity that affects between 30% and 85% of PLWH and is associated with greater odds of functional impairment, increased emergency room utilization, suboptimal retention in HIV care, and failure to achieve virologic suppression. What is not known is how to optimally address chronic pain in this population. Opioids are a commonly used treatment for chronic pain, particularly in PLWH. Opioid prescribing for chronic pain often does not result in substantial improvement in outcomes and contributes to the growing epidemic of opioid addiction and overdose. In contrast, behavioral interventions are among the most effective and safest treatments for chronic pain in the general population. Pain Self-Management (PSM) is a Social Cognitive Theory (SCT)-based behavioral approach that involves pain-related skill acquisition and goal setting. PSM interventions have been promoted by the 2016 Department of Health and Human Services National Pain Strategy (DHHS NPS) as an effective, scalable approach to chronic pain management. Especially given the current opioid crisis, the DHHS NPS underscored the urgent need to develop and test PSM interventions tailored to the unique needs of vulnerable populations, particularly PLWH, that can be implemented and disseminated nationwide. Until an effective and scalable PSM intervention for chronic pain in PLWH is developed, reducing the burden of chronic pain safely and effectively in this population will not be possible. The overall objective of this proposal is to evaluate a novel theory-based PSM intervention, "Skills TO Manage Pain" (STOMP), developed for and tailored to PLWH. The investigators will accomplish the overall objective with the following primary specific aim: 1) Evaluate the efficacy of STOMP, a theory-based intervention tailored to improving chronic pain in PLWH. Given the investigators' rigorous intervention development process and promising pilot trial results, the working hypothesis is that STOMP will decrease pain and improve function in PLWH. Investigators also propose the following secondary aims: 2) Conduct exploratory analyses of the impact of STOMP on HIV outcomes associated with chronic pain (i.e. retention in care, virologic suppression), and 3) Investigate proximal outcomes as potential mediators of STOMP's impact on chronic pain. This approach is innovative because it incorporates novel peer co-led group sessions that were created based on the investigators' formative intervention development work, includes patients with comorbidities (e.g., depressive symptoms, addiction history) common among PLWH but typically excluded from chronic pain studies, and investigates the impact of a chronic pain intervention on disease-specific HIV outcomes in addition to pain and function. The proposed research will be significant because if successful, it will pave the way for future dissemination and implementation studies that have the potential to dramatically change chronic pain treatment for PLWH.
PURPOSE:To provide a process for preparing a crude drug HANNGE (rhizome of Pinellia ternata) which is at the same level in its appearance but at the higher level in the content of a component of antiemetic activity when compared with an article on the market. CONSTITUTION:This process for preparing HANNGE comprises a treatment for removing coat of rhizome of Pinellia ternata, an acid treatment, washing with water and drying. The details of the process are as follows. After the coat is removed, a rhizome of Pinellia ternata is washed with water, dipped in an acidic aqueous solution for <=24hr, then washed for 6-48hr with running water and subsequently dried to obtain a crude drug HANNGE. The preferable pH value of the acidic aqueous solution is 0-5, especially 2-4 and aqueous solutions of acetic acid, phosphoric acid, hydrochloric acid, perchloric acid, etc., can each be used as the acidic aqueous solution. Regarding the acid treatment, the pretreated rhizome is dipped in an acidic aqueous solution preferably for <=1hr at pH0-2, for <=12hr at pH2-4 and for 12-24hr at pH4-5.
Receiving Stepped Preventive Care intervention - at least 2 brief assessments with nurse and/or social worker (1) during hospital admission , and (2) approximately 2 weeks post-discharge. Additional interventions provided as needed, based on manual.
An objective of the present application is to provide a material and a preparation method thereof, the material containing a lipophilic component having flavors or scents such as a pungent component such us capsaicin and a bitter component such as turmeric extraction. The material can efficiently suppress the flavors and/or scents of the lipophilic component without separation of the contained component. Another objective of the present application is to provide a composition such drinks, cosmetics and medicines having the material blended therein. Another objective of the present application is to provide a liquid composition having the material dispersed in water. The present application provides a complex containing a lipophilic component, a substance (A) selected from a group consisted of plant sterol, γ -orizanol, isoflavone, vitamin D, vitamin E, vitamin K and combination thereof, and cyclodextrin. Moreover, the present application provides a composition having the complex blended therein. Furthermore, the present application provides a liquid composition containing the complex, water and thickener, wherein the complex is dispersed in the water. Furthermore, the present application provides a preparation method of complex containing a lipophilic component, a substance (A) selected from a group consisted of plant sterol, γ -orizanol, isoflavone, vitamin D, vitamin E, vitamin K and combination thereof, and cyclodextrin, the method including a composite step of mixing the lipophilic component, the substance (A) and cyclodextrin in the presence of water and forming a complex.
Participants with IHS-II migraine with and/or without aura and with DSM-IV primary insomnia. They were treated for 6 weeks with 3mg eszopiclone, followed by a 2-week runout period. Participants came in for five visits: a screening visit, a randomization visit, a compliance visit, an end-treatment visit, and an exit/early termination visit.
Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate therapy.
The study intervention will be mometasone (1 mg/capsule). Participants will be required to dissolve the contents of the capsule into a 240 mL sinus rinse bottle along with the salt packet to create the rinse solution. All participants will be instructed to perform the following twice a day: irrigation of right and left nasal cavity with half of the rinse solution for each side.
Machine learning approaches using structural magnetic resonance imaging (sMRI) can be informative for disease classification, although their ability to predict psychosis is largely unknown. We created a model with individuals at CHR who developed psychosis later (CHR-PS+) from healthy controls (HCs) that can differentiate each other. We also evaluated whether we could distinguish CHR-PS+ individuals from those who did not develop psychosis later (CHR-PS-) and those with uncertain follow-up status (CHR-UNK). T1-weighted structural brain MRI scans from 1165 individuals at CHR (CHR-PS+, n = 144; CHR-PS-, n = 793; and CHR-UNK, n = 228), and 1029 HCs, were obtained from 21 sites. We used ComBat to harmonize measures of subcortical volume, cortical thickness and surface area data and corrected for non-linear effects of age and sex using a general additive model. CHR-PS+ (n = 120) and HC (n = 799) data from 20 sites served as a training dataset, which we used to build a classifier. The remaining samples were used external validation datasets to evaluate classifier performance (test, independent confirmatory, and independent group [CHR-PS- and CHR-UNK] datasets). The accuracy of the classifier on the training and independent confirmatory datasets was 85% and 73% respectively. Regional cortical surface area measures-including those from the right superior frontal, right superior temporal, and bilateral insular cortices strongly contributed to classifying CHR-PS+ from HC. CHR-PS- and CHR-UNK individuals were more likely to be classified as HC compared to CHR-PS+ (classification rate to HC: CHR-PS+, 30%; CHR-PS-, 73%; CHR-UNK, 80%). We used multisite sMRI to train a classifier to predict psychosis onset in CHR individuals, and it showed promise predicting CHR-PS+ in an independent sample. The results suggest that when considering adolescent brain development, baseline MRI scans for CHR individuals may be helpful to identify their prognosis. Future prospective studies are required about whether the classifier could be actually helpful in the clinical settings.
FIELD: medicine, immunology, biochemistry. SUBSTANCE: invention relates to methods and compositions used for enhancement of immune responses mediated by proteins fused of antibody and cytokine by means of the combined administration of prostaglandin inhibitor. Invention involves immunoconjugates of type antitelocytokine and prostaglandin inhibitor. In administration to mammal immunoconjugate induces immune response directed against preliminary taken type of cells, for example, cancer cells that as result of immunopotency by prostaglandin inhibitor gives the enhanced immune response as compared with that by a single immunoconjugate only. The advantage of invention involves application of immunoconjugates for killing solid tumors. EFFECT: valuable medicinal properties of proposed proteins. 23 cl, 6 dwg, 2 tbl, 6 ex
The invention belongs to the field of medicinal preparation and specifically provides a posaconazole double-layer osmotic pump controlled release tablet and a preparation method thereof. The tablet comprises a tablet core and a semipermeable controlled release film. The tablet core comprises a drug containing layer and a boosting layer. The drug containing layer is located inside the controlled release film which is provided with a drug releasing hole. The boosting layer is located inside the controlled release film at a place far away from the drug releasing hole. One end of the water-permeable controlled release film is provided with one or more drug releasing holes. The release curve of the preparation drug shows a zero-order release pattern, and thus the problem of drug resistance caused by long-term use of posaconazole dosage forms on the market is solved. Besides, the problems that the preparation technology is complex, the preparation cost is high, and the drug is unsuitable for industrialized mass production due to the adoption of a hot-melt extrusion technology are solved. Simultaneously, the in vivo-in vitro correlation of the drug is better ensured and the clinical monitoring of plasma concentration is better facilitated.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to medicine, particularly intraocular drug delivery systems. The system contains a number of microsphres of average diameter within 8 micron to 14 micron, an aqueous carrier for microspheres where the microspheres consist of: brimonidine, where brimonidine makes approximately 0.5 wt % to approximately 15 wt % of the microspheres, and one or more biodegradable polymers representing polymer poly(D,L)lactides with inherent viscosity 0.4 dl/g to 0.8 dl/g where PMC polymer makes 85 wt % to 99.5 wt % of the microspheres, and where the drug delivery system can be injected in an intraocular region through a needle of a syringe calibre 20-26, and the microspheres can release approximately 0.5 mcg/day to approximately 20 mcg/day of brimonidine within a period of time approximately 10 days to approximately 100 days to provide treating eye conditions. The intraocular region represents a subtenon space, a subconjunctival or retrobulbar region. ^ EFFECT: invention provides release of the therapeutic agent in a therapeutically effective amount for a period of 10 days to one year. ^ 4 cl, 13 tbl, 6 dwg, 7 ex
Recent reports suggest an association between the use of anticonvulsant drugs by women with epilepsy and an elevated incidence of birth defects in children born to these women. Data are more extensive with respect to diphenylhydantoin and phenobarbital, but these are also the most commonly prescribed anticonvulsants; less systematic or anecdotal reports suggest a possible similar association with the use of all known anticonvulsant drugs.

In children of women treated with drugs for epilepsy, reports suggesting an elevated incidence of birth defects cannot be regarded as adequate to prove a definite cause and effect relationship. There are intrinsic methodologic problems in obtaining adequate data on drug teratogenicity in humans; the possibility also exists that other factors ( eg, genetic factors or the epileptic condition itself) may be more important than drug therapy in leading to birth defects. The great majority of mothers on anticonvulsant medication deliver normal infants. It is important to note that anticonvulsant drugs should not be discontinued in patients in whom the drug is administered to prevent seizures because of the strong possibility of precipitating status epilepticus with attendant hypoxia and threat to life. In individual cases where the severity and frequency of the seizure disorder are such that the removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy; however, it cannot be said with any confidence that even mild seizures do not pose some hazards to the developing embryo or fetus.
Participants with Solid Tumors which are typically treated with cancer immunotherapy (PD-1 or PD-L1 blocking antibodies) and their cancer has progressed on immunotherapy will be candidates for the trial. This is a single-arm trial.
This disclosure describes the use of azithromycin, roxithromycin, and telithromycin, including derivatives thereof, as senolytic drugs. BrdU was used to induce senescence in model human fibroblast cell lines. Also disclosed are methods for screening compounds for senolytic activity. The SRB assay was used to measure cell viability through protein content. Azithromycin roxithromycin, and telithromycin, clinically-approved pharmaceuticals, were found to be senolytic drugs. However, the closely-related parent compound, erythromycin, showed no senolytic activity. Azithromycin strongly induced both aerobic glycolysis and autophagy in human fibroblasts, but showed bi-phasic effects including on mitochondrial oxygen consumption rates with inhibitory activity at 50 µ? and stimulatory activity at 100 µ?. The xCELLigence real-time assay system showed that azithromycin preferentially targets senescent cells, removing approximately 97% (nearly a 25-fold reduction in senescent cells).